

# 1<sup>st</sup> Quarter 2026 Earnings Presentation

May 5, 2026

---



# Cautionary Statements

---

## Forward-Looking Statements

Statements contained in this presentation, other than statements of historical fact, are forward-looking statements. These statements can be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “continues,” “estimates,” “predicts,” “projects,” “forecasts,” “may,” “could,” “plans,” “will,” “would,” and similar expressions. These forward-looking statements include, without limitation, statements regarding the anticipated timing and strength of the opportunities available to Surgery Partners, Inc. and its subsidiaries (the “Company”), as well as the future financial position of the Company, including financial targets, business strategy, plans and objectives for future operations and future operating results and cash flows. These statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those made in, or implied by, the forward-looking statements. Many of these factors are beyond our ability to control or predict including, without limitation, reductions in payments from government healthcare programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; our efforts to integrate operations of acquired or developed businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring or operating surgical facilities; the impact that legislation and other health care public policy changes, and other regulatory actions or executive orders may have on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions; changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties set forth under the heading “Risk Factors” in our 2025 Annual Report on Form 10-K and discussed from time to time in our other reports filed with the Securities and Exchange Commission (the “SEC”). You should read the Company’s annual report and all other filings with the SEC, available at [www.sec.gov](http://www.sec.gov), for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this presentation speak only as of the date of the presentation, and the Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law. No representations or warranties are made by the Company or any of its affiliates, or any of its or their respective direct or indirect subsidiaries, affiliates, stockholders, members, partners, directors, officers, employees, advisors, agents or any representatives, as to the accuracy of any such statements or projections. Investors, potential investors, and others should give careful consideration to these risks and uncertainties and should not place considerable reliance on the forward-looking statements contained in this presentation.

## Non-GAAP Financial Measures

This presentation contains certain non-GAAP financial measures. A “non-GAAP financial measure” is defined as a numerical measure of a company’s financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles in the United States (“GAAP”) in the statements of income, balance sheets or statements of cash flow of the company. We present non-GAAP financial measures when we believe that the additional information is useful and meaningful to investors. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-GAAP financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with GAAP. Reconciliations of these non-GAAP measures are included in our filings with the SEC and at the end of this presentation.

# First Quarter 2026 Highlights

**~158k**  
Surgical Cases

**\$810.9m**  
Net Revenue

**\$102.3m**  
Adjusted  
EBITDA  
12.6% Margin

Same-Facility  
4.4% Net Revenue  
0.6% Surgical Cases  
3.8% Rate



**~158k Consolidated Surgical Cases**  
0.6% Same-Facility Growth



**\$811M Net Revenue**  
4.5% Y/Y Growth  
4.4% Same-Facility Growth



**17% Total Joint Growth YoY**  
~65k Musculoskeletal<sup>1</sup> procedures



**~140 New Physician Recruits**

(1) Musculoskeletal (or "MSK") references orthopedic, spine, neurology and pain management specialties



# 2026 Financial Outlook

The Company Reaffirms its 2026 Full Year Guidance

Revenue	\$3.35b - \$3.45b
Adjusted EBITDA	\$530m+
Organic Adjusted EBITDA Growth	4.2%+
Same-Facility Revenue Growth	3.0%+

## Second Quarter 2026 Revenue

24.0% to 24.5% of mid-point of  
2026 Revenue guidance

## Second Quarter 2026 Adjusted EBITDA

23.0% to 23.5% of  
2026 Adjusted EBITDA guidance



## 2026 Adjusted EBITDA Outlook Bridge from 2025

*\$ in millions*

2025 Adjusted EBITDA	\$526
Annualize 2025 Acquisitions & Divestitures	9
Funding Annual Cash Incentive at Target	(15)
2025 Normalized Performance	\$520
Provider Tax & Medicaid Pressures	(8)
Incremental Tariff Pressures	(4)
Organic Growth	22+
2026 Adjusted EBITDA Guidance	\$530+
2026 Anticipated Growth vs 2025 Normalized	1.9%+
2026 Organic Growth vs 2025 Normalized	4.2%+

2026 organic growth and prior year capital deployment gains offset incentive plan costs and regulatory pressures

# Supplemental Non-GAAP Reconciliations

---

# Supplemental Non-GAAP Disclosures

	<b>Three Months Ended March 31, 2026</b>
<b>Loss before income taxes</b>	<b>(3.3)</b>
Plus (minus):	
Net income attributable to non-controlling interests	(33.8)
Interest expense, net	69.1
Depreciation and amortization	38.5
Equity-based compensation expense	5.8
Transaction and integration costs	15.6
De novo start-up costs	1.9
Net loss on disposals, consolidations and deconsolidations	4.3
Litigation settlements and other litigation costs	4.2
<b>Total Adjustments</b>	<b>105.6</b>
<b>Adjusted EBITDA</b>	<b>102.3</b>

We are not able to project components of 2026 Adjusted EBITDA outlook.

